title: Restricted specificity of anti-ribosomal P antibodies to SLE patients in Israel.
abstract: OBJECTIVE
  Anti-ribosomal P antibodies (aRib-P Ab) are highly specific for systemic lupus erythematosus (SLE), but their correlatation with disease activity and manifestations including renal, hepatic and central nervous system (CNS) involvement is still controversial. The aim of our study was to evaluate the prevalence of aRib-P Ab and their correlation with clinical manifestations and anti-dsDNA antibodies in SLE patients from Israel.
  
  
  METHODS
  Elevated titers of aRib-P Ab utilizing the ELISA method were analyzed in 141 sera samples from 44 SLE patients, 20 Familial Mediterranean Fever (FMF) patients, 22 primary antiphospholipid syndrome (PAPS) patients, 12 patients with infections, and 43 healthy individuals. The SLEDAI score was utilized for assessing SLE disease activity.
  
  
  RESULTS
  Elevated titers of aRib-P Ab were present in 11% of SLE patients (n = 6). The mean SLEDAI was 7 (range: 3-10). No statistically significant association was observed between the presence of aRib-P Ab and disease manifestations present in the SLEDAI. The 6 SLE patients had renal disease (n = 1), leucopenia (n = 1), rash (n = 3), and CNS involvement manifested as psychosis (n = 1) or depression (n = 1). Elevated titers of anti-dsDNA antibodies were found in 50% of patients with elevated titers of aRib- P Ab. Patients with PAPS, FMF, infections or healthy controls did not harbor elevated titers of aRib-P Ab.
  
  
  CONCLUSIONS
  Elevated titers of aRib-P Ab were restricted to SLE patients. We confirm previously reported associations of aRib-P Ab reactivity with disease activity and elevated anti-dsDNA Ab titers. No significant correlation with a specific manifestation described on the SLEDAI score was established in this small cohort of patients.
authors.affiliation: Center for Autoimmune Diseases and Dept. of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Shovman
authors.forename: G
authors.initials: G
authors.lastname: Zandman-Goddard
authors.forename: B
authors.initials: B
authors.lastname: Gilburd
authors.forename: M
authors.initials: M
authors.lastname: Blank
authors.forename: M
authors.initials: M
authors.lastname: Ehrenfeld
authors.forename: S
authors.initials: S
authors.lastname: Bardechevski
authors.forename: L
authors.initials: L
authors.lastname: Stojanovich
authors.forename: P
authors.initials: P
authors.lastname: Langevitz
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000453:epidemiology / Q000276:immunology* / Q000523:psychology; D001323:Autoantibodies / Q000032:analysis / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D010505:Familial Mediterranean Fever / Q000453:epidemiology / Q000276:immunology* / Q000523:psychology; D005260:Female; D006801:Humans; D007118:Immunoassay; D007557:Israel / Q000453:epidemiology; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology / Q000276:immunology* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000276:immunology*; D011618:Psychotic Disorders / Q000209:etiology / Q000276:immunology; D012269:Ribosomal Proteins / Q000276:immunology*; D012680:Sensitivity and Specificity
chemical_list: D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D010750:Phosphoproteins; D012269:Ribosomal Proteins; C031937:phosphoprotein P2, ribosomal; C035690:ribosomal phosphoprotein P1; C054675:ribosomal protein P0